Korean Red Ginseng in Treating Patients With Fatigue Caused by Chemotherapy for Colorectal Cancer
Launched by KOREA GINSENG CORPORATION · Jan 15, 2014
Trial Information
Current as of June 09, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 20 years and older
- • Person who agreed to participate in this study and signed voluntarily on the written informed consent form
- • Person who is confirmed as colorectal cancer through histological and image diagnosis and scheduled for adjuvant or palliative therapy with mFOLFOX-6 regimen
- • Fertile patients with negative pregnancy test confirmed and who has agreed to use effective contraception
- • Person who is able to fully communicate with the physician about his/her fatigue status and is able to completely fill out the questionnaires
- • Life expectancy more than 6 months
- • Performance status of ECOG grade 0\~1
- • Hb ≥ 9g/dL
- • Person with moderate liver function (AST, ALT ≤ 2.5 × ULN)
- • Person with moderate renal function (Cr ≤ 1.5 × ULN)
- Exclusion Criteria:
- • Pregnant or nursing women
- • Primary brain cancer, brain metastases or other CNS malignancy, including CNS lymphoma
- • No controlled pain despite the use if analgesics.
- • Person showing hypothyroidism despite the hormone treatment
- • Person with insomnia despite an appropriate treatment
- • No controlled hypertension (DBP \>100mmHg or SBP \>160mmHg)
- • Person who has experience of hypersensitivity to the trial drug (ginseng) components
- • Person with autoimmune disorders (Multiple sclerosis, Lupus, rheumarthritis etc.)
- • Person who is alcoholic dependent or has psychiatric disorder
- • Person who has cognitive or psychiatric problems
- • Person who has an experience of chemotherapy agents use 6 months before a screening visit
- • Person who had a surgery 2 weeks before a screening visit
- • Person who had taken herbal medicinal product (including Chinese medicine) 4 weeks before the screening visit
- • Person who has medical status that is judged to affect the result or who is judged as inappropriate for the study by the physician
About Korea Ginseng Corporation
Korea Ginseng Corporation (KGC) is a leading global enterprise specializing in the cultivation, research, and development of high-quality ginseng products. With a commitment to advancing health and wellness, KGC leverages its extensive expertise in herbal medicine and traditional practices to innovate and promote the therapeutic benefits of ginseng. The corporation is dedicated to rigorous scientific research and clinical trials to validate the safety and efficacy of its products, ensuring they meet the highest standards of quality and effectiveness. As a pioneer in the ginseng industry, KGC aims to enhance global health outcomes through its natural solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shinseongdong, Daejeon, Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials